Interim Report Archives

Interim Report Fourth Quarter 2023

October-December 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -54,513 thousand (-55,220) Earnings per share before dilution amounted to SEK -1.85 (-2.48) Cash flow from operating activities amounted to SEK -32,626 thousand (-35,003) Cash flow from investing activities amounted to SEK -20,729 thousand (-29,481) January-December 2023, Group […]

Interim Report Third Quarter 2023

July-September 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -38,942 thousand (-28,651) Earnings per share before dilution amounted to SEK -1.59 (-1.39) Cash flow from operating activities amounted to SEK -68,611 thousand (-23,091) Cash flow from investing activities amounted to SEK -14,470 thousand (-29,126) January-September 2023, Group […]

Interim Report Second Quarter 2023

April-June 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -51,402 thousand (-28,865) Earnings per share before dilution amounted to SEK -2.27 (-1.40) Cash flow from operating activities amounted to SEK -56,503 thousand (-24,472) Cash flow from investing activities amounted to SEK -16,027 thousand (-29,197) January-June 2023, Group […]

Interim Report First Quarter 2023

January–March 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -34,827 thousand (-18,934) Earnings per share before dilution amounted to SEK -1.54 (-0.92) Cash flow from operating activities amounted to SEK -45,535 thousand (-27,613) Cash flow from investing activities amounted to SEK -14,650 thousand (-47,541) Significant events during […]

Interim Report Fourth Quarter 2022

October–December 2022, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -55,220 thousand (-51,944) Earnings per share before dilution amounted to -2.48 SEK (-2.62) Cash flow from operating activities amounted to SEK -35,003 thousand (-10,280) Cash flow from investing activities amounted to SEK -29,481 thousand (-33,691) January–December 2022, Group […]

Interim Report Third Quarter 2022

Once again an eventful quarter July–September 2022, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -28,651 thousand (-13,890) Earnings per share before dilution amounted to SEK -1.39 (-0.73) Cash flow from operating activities amounted to SEK -23,091 thousand (-16,524) Cash flow from investing activities amounted to SEK -29,126 […]

Interim Report Second Quarter 2022

A vision to improve patients’ lives Second quarter 2022 (April–June), Group· Net sales amounted to SEK 0 thousand (0)· Loss before tax amounted to SEK -28,865 thousand (-16,952)· Earnings per share before dilution amounted to SEK -1.40 (-0.89)· Cash flow from operating activities amounted to SEK -24,472 thousand (-12,831)· Cash flow from investing activities amounted to SEK -29,197 […]

An eventful quarter sets the agenda for an intense 2022

First Quarter 2022 (January 1 – March 31), Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -18,934 thousand (-13,912) Earnings per share before dilution amounted to SEK -0.92 (-0.73) Cash flow from operating activities amounted to SEK -27,613 thousand (-11,971) Cash flow from investing activities amounted to SEK […]

Xspray Pharma publishes Q4 Year-End report 2021

”When looking back at Xspray Pharma’s fourth quarter 2021, I see it marked by hope for the future. After the end of the quarter, we reached a significant milestone when the US Food and Drug Administration (FDA) announced that it had agreed to review Xspray Pharma’s first product candidate: Dasynoc, an improved version of dasatinib. […]

Xspray Pharma publishes interim report Q3, January – September 2021

"Since the company's start, the business's focus and communication has been on generic and improved versions of PKIs. Going forward we have, after the end of the reporting period, decided to focus entirely on improved PKIs. In recent years, the value of generics in our models has gradually decreased, while the value of improved drugs […]